Novo Nordisk A/S (NYSE:NVO) is having a busy Thursday. The Danish drugmaker picked up a key European regulatory recommendation for its hemophilia A treatment and simultaneously launched a major cardiometabolic research partnership. Investors liked what they saw: the stock was trading higher on the news.

Europe Says Yes To FREHEMGO

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing authorization for FREHEMGO (denecimig). That's the regulatory green light that precedes formal EU approval, and it's a big deal for Novo's hemophilia franchise.

Denecimig is a next-generation factor VIIIa mimetic bispecific antibody. In plain English, it's designed to work as a routine prophylactic therapy to prevent or reduce bleeding episodes in adult and pediatric patients with hemophilia A, whether or not they have inhibitors.

The CHMP decision relied on data from the phase 3 FRONTIER clinical trial program. During the pivotal FRONTIER 2 study, denecimig significantly cut annualized bleeding rates compared with prior clotting factor prophylaxis and on-demand care. FRONTIER 3 confirmed similar efficacy in children under 12 years old. Across the entire program, denecimig demonstrated mean annualized bleeding rates below one, while a substantial proportion of patients achieved zero treated bleeds.

Switching From Emicizumab, And The U.S. Picture

Phase 3b data from FRONTIER 5, published in the Journal of Thrombosis and Haemostasis, showed patients safely switched from emicizumab to denecimig without requiring a loading dose or washout period. The therapy restored thrombin generation to normal ranges without inducing excessive clotting, and participants expressed a preference for denecimig's pen injector system.

On the U.S. front, Novo submitted a Biologics License Application for denecimig to the U.S. Food and Drug Administration in September 2025.

Novo Bets Up To $1.4 Billion On Orbis Medicines

Separately, Novo established a strategic licensing agreement with Eli Lilly & Co. (NYSE:LLY)-backed Orbis Medicines to design oral macrocycle drugs for cardiometabolic conditions.

Orbis may receive up to $1.4 billion in upfront fees, milestone payments, and tiered royalties. Novo will also make a direct investment in Orbis, leveraging its generative AI nGen platform to advance orally available therapeutics.

NVO Price Action: Novo Nordisk shares were up 3.09% at $43.00 at the time of publication on Thursday, according to market data.